BioSyent Inc. (BIOYF)
OTCMKTS · Delayed Price · Currency is USD
8.82
+0.04 (0.46%)
Dec 8, 2025, 9:30 AM EST
BioSyent Revenue
BioSyent had revenue of 12.22M CAD in the quarter ending September 30, 2025, with 27.90% growth. This brings the company's revenue in the last twelve months to 42.18M, up 22.22% year-over-year. In the year 2024, BioSyent had annual revenue of 35.03M with 10.89% growth.
Revenue (ttm)
42.18M CAD
Revenue Growth
+22.22%
P/S Ratio
3.29
Revenue / Employee
n/a
Employees
n/a
Market Cap
99.56M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.03M | 3.44M | 10.89% |
| Dec 31, 2023 | 31.59M | 3.67M | 13.12% |
| Dec 31, 2022 | 27.93M | -693.03K | -2.42% |
| Dec 31, 2021 | 28.62M | 6.29M | 28.15% |
| Dec 31, 2020 | 22.33M | 907.84K | 4.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| Northwest Biotherapeutics | 937.00K |
BioSyent News
- 13 days ago - BioSyent Inc. (RX:CA) Q3 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 18 days ago - BioSyent declares CAD 0.05 dividend - Seeking Alpha
- 18 days ago - BioSyent GAAP EPS of C$0.23, revenue of C$12.22M - Seeking Alpha
- 18 days ago - BioSyent Releases Financial Results for Q3 and YTD 2025 - GlobeNewsWire
- 18 days ago - BioSyent Declares Fourth Quarter 2025 Dividend - GlobeNewsWire
- 3 months ago - BioSyent Inc. (BIOYF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioSyent declares CAD 0.05 dividend - Seeking Alpha
- 3 months ago - BioSyent Releases Financial Results for Q2 and H1 2025 - GlobeNewsWire